Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Drug Safety and Relevant Issues in the Real-World"
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: 31 July 2023 | Viewed by 4182
Special Issue Editors
Interests: pharmacovigilance; pharmacoepidemiology; real-world data; adverse drug reactions; post-marketing surveillance
Interests: mechanism of action of drugs; tissue remodeling; nutraceuticals; pharmacovigilance
Special Issues, Collections and Topics in MDPI journals
Interests: pharmacology; pharmacovigilance; pharmacoepidemiology; real world
Special Issue Information
The COVID-19 pandemic showed, once again, how drug safety and proper communication in the field of pharmacovigilance play key roles in public health, especially in times of emergency. Although randomized clinical trials aim to assess drug efficacy and safety before its approval, some intrinsic limitations may be detected, such as the limited number of eligible patients and short follow-up periods, which consequently, do not reflect the real-world population. Real-world data collection from electronic health databases and the adoption of automated tools with the integration of advanced methodologies have radically changed scientific evidence by improving drug benefit–risk profile assessment in real-world setting. For this reason, pharmacovigilance and pharmacoepidemiology studies are essential to further establish the appropriate prescribing, effectiveness, drug–drug interactions, short- and long-term drug safety, and all risk minimization measures of pharmacological treatments, especially for innovative therapies. Authors are invited to submit original articles as well as systematic reviews, meta-analyses, and review articles in this Special Issue to contribute to the implementation of real-world data for public health. We look forward to receiving your contributions on drug safety.
Dr. Maria Antonietta Barbieri
Dr. Natasha Irrera
Dr. Irma Convertino
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- drug safety
- real-world data
- prescriptive appropriateness
- patients’ clinical outcomes
- adverse drug reactions